Ratings Beam Therapeutics Inc.

Equities

BEAM

US07373V1052

Market Closed - Nasdaq 04:00:00 2024-07-19 pm EDT 5-day change 1st Jan Change
25.94 USD +1.89% Intraday chart for Beam Therapeutics Inc. -3.50% -4.70%

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • Based on current prices, the company has particularly high valuation levels.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
-4.70% 2.01B
C-
+21.81% 46.49B
B-
+43.45% 42.25B
A
-2.94% 40.97B
B
+24.25% 29.94B
B
-6.75% 27.97B
C
+16.47% 27.1B
B-
+49.69% 14.58B
B+
+37.44% 13.11B
C+
-2.20% 11.96B
B+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. BEAM Stock
  4. Ratings Beam Therapeutics Inc.